High-Risk Benign Breast Lesions: Current Strategies in Management

Dupont W.D. , Page D.L. . Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312: 146–151.

Schnitt S. , Connolly J. . Pathology of benign breast disorders. In: Harris J.R. , Lippman M.E. , Morrow M. , eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.

Palli D. , Rosselli Del Turco M. . Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer. 1991; 47: 703–706.

Dupont W.D. , Parl F.F. , Hartmann W.H. . Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993; 71: 1258–1265.

Marshall L.M. , Hunter D.J. , Connelly J.L. . Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997; 6: 297–301.

Arpino G. , Laucirica R. , Elledge R.M. . Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005; 143: 446–457.

Wang J. , Costantino J.P. , Tan-Chiu E. . Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 2004; 96: 616–620.

London S.J. , Connolly J.L. , Schnitt S.J. . A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992; 267: 941–944.

Page D.L. , Salhany K.E. , Jensen R.A. . Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer. 1996; 78: 258–266.

Lewis J.T. , Hartmann L.C. , Vierkant R.A. . An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol. 2006; 30: 665–672.

Gendler L.S. , Feldman S.M. , Balassanian R. . Association of breast cancer with papillary lesions identified at percutaneous image-guided breast biopsy. Am J Surg. 2004; 188: 365–370.

Liberman L. , Tornos C. , Huzjan R. . Is surgical excision warranted after benign, concordant diagnosis of papilloma at percutaneous breast biopsy? AJR Am J Roentgenol. 2006; 186: 1328–1334.

Sydnor M.K. , Wilson J.D. , Hijaz T.A. . Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007; 242: 58–62. Epub 2006 Nov 7.

Renshaw A.A. , Derhagopian R.P. , Tizol-Blanco D.M. . Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol. 2004; 122: 217–221.

Ali-Fehmi R. , Carolin K. , Wallis T. . Clinicopathologic analysis of breast lesions associated with multiple papillomas. Hum Pathol. 2003; 34: 234–239.

King T.A. , Scharfenberg J.C. , Smetherman D.H. . A better understanding of the term radial scar. Am J Surg. 2000; 180: 428–432; discussion 432-433.

Alleva D.Q. , Smetherman D.H. , Farr G.H. . Radial scar of the breast: radiologic-pathologic correlation in 22 cases. Radiographics. 1999; 19 Spec No: S27–S35; discussion S36-S37.

Frouge C. , Tristant H. , Guinebretière J.M. . Mammographic lesions suggestive of radial scars: microscopic findings in 40 cases. Radiology. 1995; 195: 623–625.

Sewell C.W. . Pathology of benign and malignant breast disorders. Radiol Clin North Am. 1995; 33: 1067–1080.

Wellings S.R. , Alpers C.E. . Subgross pathologic features and incidence of radial scars in the breast. Hum Pathol. 1984; 15: 475–479.

Becker L. , Trop I. . David J, et al. Management of radial scars found at percutaneous breast biopsy. Can Assoc Radiol J. 2006; 57: 72–78.

Sanders M.E. , Page D.L. , Simpson J.F. . Interdependence of radial scar and proliferative disease with respect to invasive breast cancinoma risk in patients with benign breast biopsies. Cancer. 2006; 106: 1453–1461.

Mokbel K. , Price R.K. , Mostafa A. . Radial scar and carcinoma of the breast: microscopic findings in 32 cases. Breast. 1999; 8: 339–342.

Vega A. , Garijo F. . Radial scar and tubular carcinoma. Mammographic and sonographic findings. Acta Radiol. 1993; 34: 43–47.

Seidman J.D. , Ashton M. , Lefkowitz M. . Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer. 1996; 77: 2529–2537.

Bianchi S. , Palli D. , Galli M. . Reproducibility of histological diagnoses and diagnostic accuracy of non palpable breast lesions. Pathol Res Pract. 1994; 190: 69–76.

Günhan-Bilgen I. , Memifl A. , Ustün E.E. . Sclerosing adenosis: mammographic and ultrasonographic findings with clinical and histopatho-logical correlation. Eur J Radiol. 2002; 44: 232–238.

Gill H.K. , loffe O.B. , Berg W.A. . When is a diagnosis of sclerosing adenosis acceptable at core biopsy? Radiology. 2003; 228: 50–57. Epub 2003 May 8.

Jensen R.A. , Page D.L. , Dupont W.D. . Invasive breast cancer risk in women with sclerosing adenosis. Cancer. 1989; 64: 1977–1983.

Bodian C.A. , Perzin K.H. , Lattes R. . Prognostic significance of benign proliferative breast disease. Cancer. 1993; 71: 3896–3907.

Dupont W.D. , Page D.L. , Parl F.F. . Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994; 331: 10–15.

Carter B.A. , Page D.L. , Schuyler P. . No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer. 2001; 92: 30–36.

Fisher B. , Costantino J.P. , Wickerham D.L. . Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371–1388.

Vogel V.G. , Costantino J.P. , Wickerham D.L. . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295: 2727–2741. Epub 2006 Jun 5. Erratum in: JAMA. 2006;296: 2926.

Collins L.C. , Baer H.J. , Tamimi R.M. . Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses’ Health Study. Cancer. 2007; 109: 180–187.

Marshall L.M. , Hunter D.J. , Connolly J.L. . Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997; 6: 297–301.

Page D.L. , Dupont W.D. , Rogers L.W. . Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985; 55: 2698–2708.

Page D.L. , Schuyler P.A. , Dupont W.D. . Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003; 361: 125–129. Erratum in: Lancet. 2003;361: 1994.

Connolly J. , Schnitt S. , London S. . Both atypical lobular hyperplasia (ALH) and atypical ductal hyperplasia (ADH) predict for bilateral breast cancer risk. Lab Invest. 1992; 66: 13A.

Dmytrasz K. , Tartter P.I. , Mizrachy H. . The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J. 2003; 9: 10–12.

Margenthaler J.A. , Duke D. , Monsees B.S. . Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg. 2006; 192: 534–537.

Bedei L. , Falcini F. , Sanna P.A. . Atypical ductal hyperplasia of the breast: the controversial management of a borderline lesion: experience of 47 cases diagnosed at vacuum-assisted biopsy. Breast. 2006; 15: 196–202. Epub 2005 Aug 1.

Irfan K. , Brem R.F. . Surgical and mammographic follow-up of papillary lesions and atypical lobular hyperplasia diagnosed with stereotactic vacuum-assisted biopsy. Breast J. 2002; 8: 230–233.

Rosai J. . Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991; 15: 209–221.

Greene T. , Tartter P.I. , Smith S.R. . The significance of surgical margins for patients with atypical ductal hyperplasia. Am J Surg. 2006; 192: 499–501.

Simpson P.T. , Gale T. , Fulford L.G. . The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003; 5: 258–262. Epub 2003 Jul 29.

Chuba P.J. , Hamre M.R. , Yap J. . Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005; 23: 5534–5541.

Page D.L. , Kidd T.E. , Dupont W.D. . Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991; 22: 1232–1239.

Franceschi S. , Levi F. , La Vecchia C. . Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998; 77: 392–395.

Frykberg E.R. , Santiago F. , Betsill W.L. . Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987; 164: 285–301.

Shin S.J. , Rosen P.P. . Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med. 2002; 126: 697–701.

Lechner M.C. , Jackman R.J. , Brem R.F. . Lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous biopsy with surgical correlation: a multiinstitutional study. Radiology. 1999; 213: 106.

Arpino G. , Allred D.C. , Mohsin S.K. . Lobular neoplasia on core-needle biopsy: clinical significance. Cancer. 2004; 101: 242–250.

Haagensen C.D. , Lane N. , Lattes R. . Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978; 42: 737–769.

Newman L. . Lobular carcinoma in situ: clinical management. In: Harris J.R. , Lippman M.E. , Morrow M. , eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.

Bradley S.J. , Weaver D.W. , Bouwman D.L. . Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg. 1990; 56: 428–432.

Li C.I. , Malone K.E. , Saltzman B.S. . Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006; 106: 2104–2112.

Fisher E.R. , Land S.R. , Fisher B. . Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004; 100: 238–244.

Reis-Filho J.S. , Simpson P.T. , Jones C. . Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol. 2005; 207: 1–13.

Sneige N. , Wang J. , Baker B.A. . Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002; 15: 1044–1050.

Giri D.D. , Dundas S.A. , Nottingham J.F. . Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989; 15: 575–584.

Barnes R. , Masood S. . Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 1990; 94: 533–537.

Cuzick J. , Forbes J. , Edwards R. . First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002; 360: 817–824.

Powles T. , Eeles R. , Ashley S. . Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998; 352: 98–101.

Veronesi U. , Maisonneuve P. , Costa A. . Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352: 93–97.

Bao T. , Prowell T. , Stearns V. . Chemoprevention of Breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther. 2006; 13: 337–348.

Cuzick J. , Powles T. , Veronesi U. . Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296–300.

Cummings S.R. , Eckert S. , Krueger K.A. . The effect on raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Mutiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189–2197. Erratum in: JAMA. 1999 Dec 8;282(22): 2124.

Martino S. , Cauley J.A. , Barrett-Conner E. . Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751–1761.

Premkumar A. , Venzon D. , Avila N. . Gynocologic and hormonal effects of raloxifene in premenopausal subjects at high risk of developing breast cancer. AJR Am J Roentgenol. 2006; 186(Suppl 4): A121.

Geller B.A. , Vogel V.G. . Chemoprevention of breast cancer in postmenopausal women. Breast Dis. 2005-2006;24: 79–92.

Goss P.E. , Ingle J.N. , Martino S. . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 1793–1802. Epub 2003 Oct 9.

Baum M. , Buzdar A. , Cuzick J. . Anastrozole alone or in combination with tamoxifen verses tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003; 98: 1802–1810.

Coombes R.C. , Hall E. , Gibson L.J. . A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081–1092. Erratum in: N Engl J Med. 2004;351: 2461.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B. , Keshaviah A. . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 2747–2757.

Goss P.E. , Ingle J.N. , Martino S. . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005; 97: 1262–1271.

Howell A. , Cuzick J. , Baum M. . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005; 365: 60–62.

Kendall A. , Dowsett M. . Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Rel Cancer. 2006; 13: 827–837.

Terry M.B. , Gammon M.D. , Zhang F.F. . Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004; 291: 2433–2440.

DuBois R.N. . Aspirin and breast cancer prevention: the estrogen connection. JAMA. 2004; 291: 2488–2489.

Thompson H.J. , Herbst E.J. , Meeker L.D. . Effect of D, L-alpha-diflu-oromethylornithine on murine mammary carcinogenesis. Carcinogenesis. 1984; 5: 1649–1651.

Green J.E. , Shibata M.A. , Shibata E. . 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001; 61: 7449–7455.

Fabian C.J. , Kimler B.F. , Brady D.A. . A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002; 8: 3105–3117.

Moon R.C. , Pritchard J.F. , Mehta R.G. . Suppression of rat mammary cancer development by N-(4-hydroxyphenyl) retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis. 1989; 10: 1645–1649.

Mehta R.G. , Moon R.C. , Hawthorne M. . Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer. 1991; 27: 138–141.

Veronesi U. , De Palo G. , Marubini E. . Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999; 91: 1847–1856.

Jeffrey S.S. , Pollack J.R. . The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res. 2003; 5: 320–328. Epub 2003 Oct 9.